Literature DB >> 9726676

Effects of betahistine on vestibular receptors of the frog.

L Botta1, E Mira, S Valli, P Perin, G Zucca, P Valli.   

Abstract

Betahistine is widely used in the symptomatic treatment of peripheral and central vestibular disorders. However, its remains unknown whether the drug can act directly on inner ear sensory organs. To this end, the effects of betahistine (10(-7)-10(-2) M) were examined on isolated preparations of frog semicircular canal mounted in a double-celled bath which allowed drug administration both in the endolymphatic and in the perilymphatic fluid. The effects of betahistine were evaluated by recording ampullar receptor potentials and nerve firing rate both at rest and during mechanical stimulation of the isolated preparation. The results demonstrated that endolymphatic administration of betahistine had no effect, whereas its perilymphatic administration could reduce greatly ampullar receptor resting discharge but had little effect on mechanically evoked responses. This observation may explain the anti-vertigo effects of betahistine. Vertigo is normally due to uncontrolled changes in vestibular receptor resting discharge. It is therefore probable that any factor able to reduce the resting firing rate of vestibular receptors and, in consequence, its variations, may have an anti-vertigo action.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9726676     DOI: 10.1080/00016489850154658

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  8 in total

1.  Meta-analysis of clinical studies with betahistine in Ménière's disease and vestibular vertigo.

Authors:  Jozef J P Nauta
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-06-19       Impact factor: 2.503

2.  Histamine H4 receptor antagonists as potent modulators of mammalian vestibular primary neuron excitability.

Authors:  G Desmadryl; S Gaboyard-Niay; A Brugeaud; C Travo; A Broussy; A Saleur; J Dyhrfjeld-Johnsen; E Wersinger; C Chabbert
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

Review 3.  Histamine and betahistine in the treatment of vertigo: elucidation of mechanisms of action.

Authors:  M Lacour; O Sterkers
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

4.  Neuropharmacology of vestibular system disorders.

Authors:  Enrique Soto; Rosario Vega
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

Review 5.  Pharmacological treatment of vertigo.

Authors:  Timothy C Hain; Mohammed Uddin
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 6.  Electrophysiological Measurements of Peripheral Vestibular Function-A Review of Electrovestibulography.

Authors:  Daniel J Brown; Christopher J Pastras; Ian S Curthoys
Journal:  Front Syst Neurosci       Date:  2017-05-31

7.  Effect of a fixed combination of nimodipine and betahistine versus betahistine as monotherapy in the long-term treatment of Ménière's disease: a 10-year experience.

Authors:  D Monzani; M R Barillari; M Alicandri Ciufelli; E Aggazzotti Cavazza; V Neri; L Presutti; E Genovese
Journal:  Acta Otorhinolaryngol Ital       Date:  2012-12       Impact factor: 2.124

8.  Betahistine in the treatment of Ménière's disease.

Authors:  Michel Lacour; Paul H van de Heyning; Miroslav Novotny; Brahim Tighilet
Journal:  Neuropsychiatr Dis Treat       Date:  2007-08       Impact factor: 2.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.